Colin Broom

Dr Broom has been Chief Executive Officer of Pulmotect, Inc. since September 2019. He was Chief Executive Officer of Nabriva between 2014 and 2018. Over the past 30 years, he has been involved in all stages of drug development and commercialization. He served as Chief Scientific Officer at ViroPharma Inc., (now Shire/Takeda) between 2004 and 2014. Previous positions have included a range of leadership roles with Amgen, Hoechst Marion Roussel (now Sanofi), SmithKline Beecham and with Glaxo (now GlaxoSmithKline). He has a BSc in Pharmacology from University College, London and a Bachelor of Medicine and Surgery degree from St. George’s Hospital Medical School, London. He is a member of the UK Royal College of Physicians and a fellow of the Faculty of Pharmaceutical Medicine.